NEW
YORK, Feb. 10, 2025 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ:
HOTH), a biopharmaceutical company dedicated to
developing innovative therapies for unmet medical needs, today
announced its collaboration with OnTargetx R&D Inc. to advance
research for its cancer-fighting therapeutic, HT-KIT. This
immunohistochemistry study, conducted in partnership with Charles
River Laboratories Montreal ULC, represents a key step in the
preclinical development of HT-KIT.
The study focuses on:
Development and optimization of staining methods for (c-Kit)
markers, a critical target in HT-KIT therapeutic mechanism.
Processing and qualitative evaluation of tissue samples by a
board-certified pathologist to determine the presence of
markers.
Comprehensive reporting and insights to support the continued
development of HT-KIT.
"This partnership is instrumental in our efforts to advance
HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer
treatments," said Robb Knie, CEO at
Hoth Therapeutics. "We are committed to driving innovative
solutions that can transform patient care."
The study aligns with Hoth Therapeutics' mission to accelerate
groundbreaking therapies and address unmet medical needs in
oncology.
About HT-KIT
HT-KIT is Hoth's preclinical therapeutic candidate targeting
c-Kit, a receptor tyrosine kinase involved in various cancers. This
candidate represents a potential advancement in precision oncology
therapies.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative, impactful, and
ground-breaking treatments with a goal to improve patient quality
of life. We are a catalyst in early-stage pharmaceutical research
and development, elevating drugs from the bench to pre-clinical and
clinical testing. Utilizing a patient-centric approach, we
collaborate and partner with a team of scientists, clinicians, and
key opinion leaders to seek out and investigate therapeutics that
hold immense potential to create breakthroughs and diversify
treatment options. To learn more, please visit
https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release
includes forward-looking statements based upon Hoth's
current expectations, which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product
candidates and any other product
candidates we may develop, and the labeling
under any approval we may
obtain; the timing and costs of clinical trials,
and the timing
and costs of other expenses; market acceptance
of our products; the ultimate impact
of the current coronavirus pandemic,
or any other health epidemic, on our business,
our clinical trials, our research programs, healthcare systems, or
the global economy as a whole; our intellectual property; our
reliance on third-party organizations; our competitive position;
our industry environment; our anticipated financial and operating
results, including anticipated sources of revenues; our assumptions
regarding the size of the available market, benefits of our
products, product pricing, and timing of product launches;
management's expectation with respect to future acquisitions;
statements regarding our goals, intentions, plans, and
expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct.
Actual results may differ materially from those indicated by these forward-looking statements as a result of
various important factors, including, without limitation,
market conditions and the
factors described in the section titled "Risk
Factors" in Hoth's most recent Annual Report on Form 10-K and
Hoth's other filings made with the U. S. Securities and Exchange
Commission. All such statements speak only as of the date made.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates, and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance,
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-partners-with-ontargetx-rd-to-advance-research-for-cancer-fighting-ht-kit-cancer-therapeutic-302372193.html
SOURCE Hoth Therapeutics, Inc.
